Prazepam 10mg tablets

Introduction Sleep disturbances are a frequent and disabling symptom of pregabalin withdrawal and represent a major risk factor for relapse. In the absence of specific therapeutic recommendations, various pharmacological strategies are used in clinical practice to improve withdrawal-related comfort. Objective This study aims to compare the effects of amitriptyline and prazepam on sleep quality in patients with pregabalin use disorder. Materials and Methods This was an open-label comparative study including 40 patients managed in an addiction medicine unit. Patients were divided into two groups receiving either amitriptyline or prazepam as part of a medically supervised withdrawal program. Sleep quality was assessed at baseline and at day 30 using the Pittsburgh Sleep Quality Index (PSQI). A comparative statistical analysis was performed, with the type I error rate (α) set at 5% (p < 0.05). Results A significant improvement in the global PSQI score was observed in both groups after 30 days of treatment. No statistically significant difference was found between the two groups regarding the global PSQI score. However, sleep onset latency was significantly shorter in patients treated with amitriptyline. Conclusion Both amitriptyline and prazepam appear to be effective options for improving sleep quality during pregabalin withdrawal. Amitriptyline may represent a valuable non-benzodiazepine alternative, particularly in patients with predominant sleep-onset insomnia. Larger-scale studies are needed to confirm these findings.

Abstract licence: CC BY

BACKGROUND: The increasing global prevalence of mental disorders as well as a persistent stigma make mental disorders a public health priority. The aim of this study was to provide a comprehensive overview of psychotropic drugs utilization from 2006 to 2021 in the Republic of Serbia, examining both pre pandemic and pandemic-related changes. METHODS: To conduct this descriptive study, publicly available data on psychotropic drugs were retrieved from the official website of the Agency for Medicines and Medical Devices of Serbia (ALIMS). The linear and joinpoint regression were used in data analysis. RESULTS: A total of 54 psychotropic drugs use was analyzed from 2006 to 2021. There was an increase in the consumption of antidepressants, atypical antipsychotics, anxiolytics, sedatives, hypnotics, anti-dementia drugs and gabapentinoid-based drugs. The increase in the consumption of the psychotropic drugs was linear, with no differences between the pre-COVID-19 period and the COVID-19 pandemic. Contrary, a significant decrease in use was observed for some antidepressants (maprotiline, moclobemide, mianserin), antipsychotics (chlorpromazine, fluphenazine), psychostimulants and nootropic drugs (piracetam), anxiolytics (diazepam, prazepam), sedatives and hypnotics (midazolam). CONCLUSION: The COVID-19 pandemic did not contribute to change in consumption of psychotropic drugs in Serbia. Still, the use of antidepressants, atypical antipsychotics, anxiolytics, sedatives, hypnotics, anti-dementia drugs and gabapentinoids increased from 2006 to 2021.

Abstract licence: CC BY

Introduction : En France, la consommation de benzodiazépines et apparentés (BZD) reste importante malgré des recommandations de la Haute autorité de santé (HAS). Différentes stratégies de sevrage sont recommandées : diminution progressive de la BZD ou substitution vers le diazépam dans certaines situations. Le prazépam peut être également une molécule intéressante (demi-vie longue, forme galénique buvable, moins de risque d’abus que le diazépam). L’objectif de ce travail est de décrire l’efficacité, la survenue d’effets indésirables et la faisabilité d’un programme de sevrage des BZD avec une substitution par le prazépam. Matériel et méthode : Les données ont été recueillies de façon rétrospective parmi les patients hospitalisés à la clinique Saint Barnabé en 2022 ayant reçu du prazépam pour sevrage. Le sevrage est considéré comme réussi à la sortie d’hospitalisation dans le cas d’une diminution de plus de 50 % de la posologie initiale de prazépam ou d’un arrêt total de prazépam. Résultats : Parmi les 86 patients, la majorité avait des comorbidités psychiatriques et addictologiques. Parmi eux, 55 % consommaient une BZD depuis plus d’un an, 36 % au moins deux BZD et 15 % à des doses supérieures à l’autorisation de mise sur le marché (AMM). À la sortie d’hospitalisation (médiane de 42 jours), 62 % des patients avaient un sevrage réussi : 29 % ont été sevrés et 33 % ont diminué de plus de 50 % leur posologie. Le protocole a été adapté pour 38 % des patients et 27 % ont présenté des signes de sevrage. Plusieurs facteurs étaient significativement associés à un sevrage partiellement réussi ou échec : présence de trouble de la personnalité, hospitalisation dans un contexte de trouble d’usage de cocaïne, signes de sevrage et adaptation du protocole. Discussion : Ce travail met en avant l’intérêt du prazépam dans une population à risque de sevrage compliquée. La survenue de signes cliniques et d’adaptations du protocole soulignent l’importance d’une prise en charge individualisée avec une réévaluation médicale régulière. Introduction: In France, the consumption of benzodiazepines (BZD) remains significant despite Haute autorité de santé (French National Authority of Health – HAS) recommendations. Various strategies are recommended: gradual dosage reduction of the BZD consumed or switch to diazepam in certain situations. Prazepam may also be an interesting molecule (long half-life, oral solution, less risk of abuse than diazepam). The aim of this study is to describe the efficacy, adverse events and feasibility of a BZD withdrawal program with prazepam. Materials and methods : Data were collected retrospectively among patients hospitalized at the Saint Barnabé clinic in 2022, which had a prescription of prazepam for withdrawal purposes. Withdrawal was considered successful at discharge if the initial prazepam dosage was reduced by more than 50%, or if prazepam was stopped. Results: Most of the 86 patients had psychiatric or addictive comorbidities. Among them, 55% had been using BZDs for over a year, 36% consumed at least two BZDs, and 15% took doses exceeding authorized indications. At discharge (median of 42 days), 29% of patients were fully withdrawn, and 33% had reduced their initial prazepam dosage by more than 50%. The protocol was adapted in 38% of patients, and 27% experienced withdrawal symptoms. Several factors were significantly associated with partially successful or no success: presence of personality disorder, hospitalization in a context of cocaine use disorder, signs of withdrawal and protocol adaptation. Discussion: This study highlights the utility of prazepam in BZD withdrawal among a population at high risk for complicated withdrawal. The occurrence of clinical symptoms and protocol adjustments emphasize the importance of individualized management with regular medical reassessment.

Abstract licence: CC BY